The company has also received Healthcare Common Procedural Coding System (HCPCS) codes from the Centers for Medicare and Medicaid Services (CMS) for the new Medihoney dressings.

Medihoney hydrogel dressings have been developed for the treatment of dry to lightly exuding wounds.

Derma said the new dressing have been designed and manufactured to provide a reimbursable honey-based wound care dressing with clinical benefits.

The company will continue to sell existing Medihoney HCS dressings for the patients and clinicians in the acute care and private markets.

The company also produces TCC-EZ, a total contact casting system for diabetic foot ulcers.

Derma Sciences executive chairman and interim principal executive officer Stephen Wills said: Medihoney Hydrogel is the only medicinal honey-based dressing in the market offering Medicare Part B reimbursement.

“These dressings, which include four SKUs of Medihoney Hydrogel, are the first of three products we are reformulating to conform to HCPCS codes.”

Derma Sciences’ advanced wound care business president Russell Olsen said: “We are excited to be able to again offer Medihoney dressings with reliable Medicare reimbursement following the removal of reimbursable HCPCS codes last year.”

The company is also engaged in the development and commercialization of novel regenerative products derived from placental/birth tissues for use in a range of clinical applications, including the treatment of complex chronic wounds, acute wounds and localized areas of injury or inflammation.